Table 4.

Multivariable regression analysis of factors affecting outcome for patients treated with immunotherapy (N = 77 with TMB available)

Group	OR (95% CI)	P value
Rate of SD ≥ 6 month/PR/CR
Cutaneous SCC versus others	3.96 (0.69–22.64)	0.12
TMB ≥ 10 mutations/mb versus < 10	4.51 (1.40–14.61)	0.01
PD-1/L1 monotherapy versus combination	0.15 (0.04–0.58)	0.006
Progression-free survival
Male versus female	0.94 (0.53–1.68)	0.83
Caucasian versus others	0.69 (0.33–1.43)	0.32
NSCLC versus others	1.52 (0.86–2.67)	0.15
Cutaneous SCC versus others	0.71 (0.22–2.26)	0.56
TMB ≥ 10 mutations/mb versus others	0.47 (0.26–0.86)	0.01
PHBR < 0.5 versus ≥ 0.5	0.75 (0.41–1.38)	0.36
Overall survival
Male versus female	0.64 (0.33–1.26)	0.20
Caucasian versus others	0.68 (0.27–1.72)	0.42
TMB ≥ 10 mutations/mb versus < 10	0.48 (0.24–0.970)	0.04

Variables with P value of ≤ 0.1 in univariate (Table 2) were included in the multivariable regression analysis

Abbreviations: CR complete response, HR hazard ratio, NSCLC non-small cell lung cancer, OR odds ratio, PHBR Patient Harmonic-mean Best Rank, PR partial response, SCC squamous cell carcinoma, SD stable disease, TMB tumor mutational burden